Literature DB >> 33350054

Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, Scotland.

Philip W Jenkinson1,2, Nikolas Plevris1, Mathew Lyons3, Rebecca Grant3, James Fulforth1, Kate Kirkwood4, Ian D Arnott1, David Wilson5, Angus J M Watson2, Gareth-Rhys Jones1, Charlie W Lees1.   

Abstract

AIM: Biological treatment is effective in maintaining remission in ulcerative colitis (UC), although the effect on colectomy rates remains unclear. In the UK the use of antitumour necrosis factor and anti-α4β7 treatments for maintenance therapy in UC was restricted until 2015. The aim of this study was to describe the impact that this change in the prescribing of biologicals had on colectomy rates for UC.
METHOD: All patients (adult and paediatric) with a diagnosis of UC who received maintenance biological treatment and/or underwent a colectomy in Lothian, Scotland between 2005 and 2018 were identified. Linear and segmental regression analyses were used to identify the annual percentage change (APC) and temporal trends (statistical joinpoints) in biological prescription and colectomy rates.
RESULTS: Rates of initiation of maintenance biological therapy increased from 0.05 per 100 UC patients in 2005 to 1.26 in 2018 (p < 0.001). Colectomy rates per 100 UC patients fell from 1.47 colectomies in 2005 to 0.44 in 2018 (p < 0.001). The APC for colectomy decreased by 4.1% per year between 2005 and 2014 and by 18.9% between 2014 and 2018. Temporal trend analysis (2005-2018) identified a significant joinpoint in colectomy rates in 2014 (p = 0.019).
CONCLUSION: The use of maintenance biological therapy increased sharply following the change in guidance. This has been paralleled by a significant reduction in the rates of colectomy over the same time period.
© 2020 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  adalimumab; anti-TNF; biologic; colectomy; golimumab; infliximab; surgery; ulcerative colitis; vedolizumab

Mesh:

Substances:

Year:  2021        PMID: 33350054     DOI: 10.1111/codi.15491

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.917


  3 in total

1.  Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?

Authors:  Eun Soo Kim
Journal:  Gut Liver       Date:  2021-03-15       Impact factor: 4.519

2.  The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.

Authors:  Mohammed Deputy; Kapil Sahnan; Guy Worley; Komal Patel; Violeta Balinskaite; Alex Bottle; Paul Aylin; Elaine M Burns; Ailsa Hart; Omar Faiz
Journal:  Aliment Pharmacol Ther       Date:  2022-02-07       Impact factor: 9.524

3.  Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.

Authors:  Mathew Lyons; Lauranne A A P Derikx; James Fulforth; Sophie McCall; Nikolas Plevris; Philip W Jenkinson; Kathryn Kirkwood; Spyros Siakavellas; Laura Lucaciu; Nathan Constantine-Cooke; Ian D Arnott; Paul Henderson; Richard K Russell; David C Wilson; Charlie W Lees; Gareth-Rhys Jones
Journal:  Aliment Pharmacol Ther       Date:  2022-03-17       Impact factor: 9.524

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.